 Nemaura Medical, Inc. NASDAQ: NMRD Nemaura or the Company, a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT, its non-invasive and flexible continuous glucose monitor CGM, together with BEATTMdiabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today issued a presentation outlining how CGM is being used by quarantined and hospitalised COVID-19 patients. 